By Cristina Gallardo
Novo Nordisk launched NovoCare Pharmacy, to deliver doses of its weight-loss Wegovy drug directly to its users, in a bid to reduce its cost.
The Danish pharmaceutical company said Wednesday that the new direct-to-patient delivery option will allow Wegovy users to receive all dose strengths of the drug at a reduced cost of $499 per month.
Uninsured patients and those with insurance that doesn't cover obesity drugs would also be able to make use of this offer, the group said.
NovoCare Pharmacy arrives at a time of increased competition in the booming market for weight-loss drugs, still led by Eli Lilly and Novo Nordisk, which nonetheless are seeing smaller rivals such as Roche, Pfizer and Amgen striving to challenge them.
The announcement comes a couple of weeks after the U.S. Food and Drug Administration declared that the shortage of Novo Nordisk's blockbuster GLP-1 drugs, Wegovy and Ozempic, had been resolved.
All dose strengths of Wegovy are either meeting or surpassing current and projected U.S. demand, the pharmaceutical company said.
Shares in Novo Nordisk were up 2.3% at 630.10 Danish kroner in afternoon trading.
Write to Cristina Gallardo at cristina.gallardo@wsj.com
(END) Dow Jones Newswires
March 05, 2025 09:57 ET (14:57 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.